Metabolomic Profiling in Prostate Cancer Diagnostics

Metabolomic profiling has emerged as a transformative approach for the diagnosis and stratification of prostate cancer, leveraging comprehensive analyses of small-molecule metabolites to capture tumour-specific biochemical alterations. By examining metabolites in tissues, blood or urine, researchers can distinguish malignant from benign states, assess tumour aggressiveness and identify molecular subtypes. Advances in analytical platforms—including mass spectrometry and nuclear magnetic resonance spectroscopy—coupled with sophisticated data-processing algorithms, have enabled the detection of subtle changes in lipid, amino acid and energy-metabolism pathways. Integration with transcriptomic and lipidomic data deepens mechanistic understanding, revealing, for example, dysregulated cholesteryl ester accumulation and altered acylcarnitine profiles linked to cancer progression. Clinically, metabolomic signatures promise non-invasive biomarker panels to refine risk stratification, guide biopsy decisions and personalise treatment. The global significance of this field lies in its potential to reduce overdiagnosis, optimise therapeutic interventions and uncover novel metabolic targets for advanced prostate cancer management.

Research from Nature Portfolio

Recent studies have exploited integrated lipidomic and transcriptomic analyses of paired prostate tumour and adjacent non-tumour tissues to map lipid metabolic reprogramming. These investigations revealed pronounced accumulation of cholesteryl esters, notably cholesteryl oleate, which correlated with tumour progression and metastatic potential. Alterations in expression of lipid-uptake receptors and biosynthetic enzymes underpinned the observed lipid compositional shifts. Validated biomarker panels based on cholesteryl ester levels demonstrated superior diagnostic discrimination between malignant and benign tissues compared with standard prostate-specific antigen measurements, indicating strong promise for clinical translation.

Metabolomic Profiling in Prostate Cancer Diagnostics publication trend

The graph below shows the total number of articles in metabolomic profiling in prostate cancer diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomic profiling: Comprehensive analysis of small-molecule metabolites in biological samples to characterise biochemical states.

Lipidomics: Subfield of metabolomics focused on systematic study of lipid species and their roles in cellular processes.

Nuclear magnetic resonance (NMR) spectroscopy: Technique exploiting nuclear magnetic properties to identify and quantify metabolites.

High-resolution magic angle spinning (HR MAS): NMR method involving rapid sample rotation at the magic angle to achieve high spectral resolution in intact tissues.

Kendrick mass defect filtering: Computational strategy in mass spectrometry that normalises mass defects to group homologous series of compounds.

Acylcarnitines: Esters of carnitine central to mitochondrial fatty acid transport and β-oxidation, reflecting cellular energy metabolism.

Random forest: Ensemble machine-learning algorithm constructing multiple decision trees for robust classification or regression.

References

1. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer. Frontiers in Immunology (2023).
2. An untargeted analytical workflow based on Kendrick mass defect filtering reveals dysregulations in acylcarnitines in prostate cancer tissue. Analytica Chimica Acta (2024).
3. An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy. The Journal of Clinical Endocrinology & Metabolism (2024).
4. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes. Journal of Translational Medicine (2023).